Volastra Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
45
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$15M
- Investors
-
11
Volastra General Information
Description
Operator of a drug discovery and therapeutics company intended to treat and prevent the formation of metastatic disease. The company combines artificial intelligence, bioinformatics, and proprietary imaging techniques to identify which cancers are more likely to spread, enabling healthcare professionals to identify targets quicker, select the appropriate patients for therapy effectively, and improve patient outcomes.
Contact Information
Website
www.volastratx.comCorporate Office
- 1361 Amsterdam Avenue
- Suite 520
- New York, NY 10027
- United States
Corporate Office
- 1361 Amsterdam Avenue
- Suite 520
- New York, NY 10027
- United States
Volastra Timeline
Volastra Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 30-May-2024 | $15M | 00000 | Completed | Clinical Trials - Phase 1 | |
| 2. Early Stage VC (Series A) | 03-Feb-2023 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 1. Seed Round | 06-Apr-2021 | $44M | $44M | 000.00 | Completed | Clinical Trials - Phase 1 |
Volastra Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Seed | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
Volastra Comparisons
Industry
Financing
Details
000000
000000
Volastra Competitors (67)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| CytImmune Sciences | Private Equity-Backed | Rockville, MD | 0 | 000.00 | 000000000000 | 000.00 |
| Nanospectra | Venture Capital-Backed | Houston, TX | 0 | 000.00 | 00000000000 | 000.00 |
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. |
Volastra Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Volastra Patents
Volastra Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230382889-A1 | Compounds for inhibiting kif18a | Pending | 28-Apr-2022 | 0000000000 | |
| US-20230117405-A1 | Systems and methods for evaluation of chromosomal instability using machine-learning | Pending | 22-Sep-2021 | 0000000000 | |
| US-20230147507-A1 | Indoline compounds for inhibiting kif18a | Active | 26-Aug-2021 | 0000000000 | |
| AU-2022334480-A1 | Spiro indoline inhibitors of kif18a | Pending | 26-Aug-2021 | 0000000000 | |
| CA-3230123-A1 | Spiro indoline inhibitors of kif18a | Pending | 26-Aug-2021 | C07D401/12 |
Volastra Executive Team (11)
| Name | Title | Board Seat |
|---|---|---|
| Charles Hugh-Jones MD | Chief Executive Officer and Board Member | |
| Joseph Avallone | Controller | |
| Rachel Schwartz | Chief Business Officer & Head of Operations | |
| Michael Su Ph.D | Executive Officer & Independent Advisor | |
| Olivier Elemento Ph.D | Co-Founder & Scientific Advisor |
Volastra Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amy Schulman JD | Polaris Partners | Board Member | 000 0000 |
| Arjun Balar | Self | Board Member | 000 0000 |
| Charles Hugh-Jones MD | Volastra | Chief Executive Officer and Board Member | 000 0000 |
| David Nicholson Ph.D | Self | Board Member | 000 0000 |
| Ellie McGuire | Self | Board Member | 000 0000 |
Volastra Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Volastra Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| B Capital Group | Venture Capital | Minority | 000 0000 | 000000 0 |
| Cornell University | University | Minority | 000 0000 | 000000 0 |
| Eli Lilly and Company | Corporation | Minority | 000 0000 | 000000 0 |
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
| Catalio Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 |
Volastra FAQs
-
When was Volastra founded?
Volastra was founded in 2019.
-
Who is the founder of Volastra?
Olivier Elemento Ph.D, Samuel Bakhoum Ph.D, and Lewis Cantley Ph.D are the founders of Volastra.
-
Who is the CEO of Volastra?
Charles Hugh-Jones MD is the CEO of Volastra.
-
Where is Volastra headquartered?
Volastra is headquartered in New York, NY.
-
What is the size of Volastra?
Volastra has 45 total employees.
-
What industry is Volastra in?
Volastra’s primary industry is Drug Discovery.
-
Is Volastra a private or public company?
Volastra is a Private company.
-
What is Volastra’s current revenue?
The current revenue for Volastra is 00000.
-
How much funding has Volastra raised over time?
Volastra has raised $119M.
-
Who are Volastra’s investors?
B Capital Group, Cornell University, Eli Lilly and Company, ARCH Venture Partners, and Catalio Capital Management are 5 of 11 investors who have invested in Volastra.
-
Who are Volastra’s competitors?
NexImmune, CytImmune Sciences, Nanospectra, TScan Therapeutics, and Sorrento Therapeutics are some of the 67 competitors of Volastra.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
